MRNA Stock Analysis: Buy, Sell, or Hold?
MRNA - Moderna, Inc. Common Stock
$60.57
0.76 (1.27%)
▲
5d:
+6.28%
30d:
-9.61%
90d:
+14.54%
BUY
MODERATE Confidence
Analysis Updated: Aug 11, 2026 12:00 AM ET
Earnings: Jul 31, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 7, 2026 at $59.17 · last confirmed Aug 11, 2026
Strength: 8.0/10
Get Alerted When MRNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MRNA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MRNA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MRNA is currently trading at $60.57, which is considered fair relative to its 30-day fair value range of $54.17 to $70.03.
Technical Outlook: Technically, MRNA is in a uptrend. The price is approaching resistance at $61.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MRNA scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. However, the stock is trading significantly above the average Wall Street target of $50.84. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MRNA is in a uptrend. The price is approaching resistance at $61.40. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MRNA scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. However, the stock is trading significantly above the average Wall Street target of $50.84. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$54.17 -
$70.03
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
76.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 16.1% above Wall St target ($50.84)
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$54.17 -
$70.03
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$52.66
Resistance Level
$61.40
Current Trend
Uptrend
Technical data as of
Aug 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.34
Wall Street Target
$50.84
(-16.1%)
Revenue Growth (YoY)
2.1%
Earnings Growth (YoY)
-85.1%
Profit Margin
-141.4%
Share & Embed Analysis
Last updated: August 12, 2026 3:05 AM ET
Data refreshes hourly during market hours. Next update: 4:05 AM
Data refreshes hourly during market hours. Next update: 4:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Stephen Hoge
SELL
160009 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 47 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$106 | 52 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
Advanced MRNA Option Strategies
Professional options setups generated by AI based on today's MRNA price and gamma walls.
